BioNTech SE (BNTX) Cost of Revenue (2018 - 2025)

BioNTech SE has disclosed Cost of Revenue across 8 years of filings, most recently posting $388.0 million for Q4 2025.

• Cost of Revenue for Q4 2025 came in at $388.0 million, up 49.11% year-over-year; the trailing twelve-month figure through Dec 2025 was $736.0 million (up 25.75% YoY), and the FY2025 annual result was $725.1 million, up 25.36% from the prior year.
• Cost of Revenue came in at $388.0 million for Q4 2025 at BioNTech SE, up from $173.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $2050.6 billion in Q1 2021 to a low of $64.2 million in Q1 2024.
• The 5-year median for Cost of Revenue is $194.6 million (2023), against an average of $102.9 billion.
• Across the five-year window, Cost of Revenue surged 31483482.83% in 2021 and plunged 99.93% in 2022, its largest moves.
• BioNTech SE's Cost of Revenue stood at $667.2 million in 2021, then sank by 71.94% to $187.2 million in 2022, then climbed by 2.93% to $192.7 million in 2023, then surged by 35.03% to $260.2 million in 2024, then surged by 49.11% to $388.0 million in 2025.
• The last three Cost of Revenue figures came in at $388.0 million (Q4 2025), $173.4 million (Q3 2025), and $86.5 million (Q2 2025), per Business Quant data.